Cargando…

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy

BACKGROUND: Tacrolimus (TAC) is beneficial for patients with idiopathic membranous nephropathy (IMN). It has a narrow therapeutic concentration range and many factors influence TAC blood concentration. CYP3A5 is the most important enzyme in TAC metabolism. The aim of this study was to analyze the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chengning, Duan, Suyan, Guo, Miao, Yuan, Yanggang, Huang, Zhimin, Zhu, Jingfeng, Sun, Bin, Zhang, Bo, Xing, Changying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186213/ https://www.ncbi.nlm.nih.gov/pubmed/32368128 http://dx.doi.org/10.2147/PGPM.S247892

Ejemplares similares

The thickness of glomerular basement membrane predicts complete remission in primary membranous nephropathy
por: Duan, Suyan, et al.
Publicado: (2023)

Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy
por: Zhu, Huanhuan, et al.
Publicado: (2020)

Serum 25-hydroxyvitamin D as a predictive biomarker of clinical outcomes in patients with primary membranous nephropathy
por: Duan, Suyan, et al.
Publicado: (2023)

Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease
por: Duan, Suyan, et al.
Publicado: (2021)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes
por: Duan, Suyan, et al.
Publicado: (2022)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
por: Cui, W., et al.
Publicado: (2017)

Association of Glomerular Complement C4c Deposition With the Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes
por: Duan, Suyan, et al.
Publicado: (2020)

Value of monitoring urine ammonia at time of biopsy in patients with lupus nephritis
por: Zhu, Huanhuan, et al.
Publicado: (2020)

Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder
por: Nie, Guangyan, et al.
Publicado: (2022)

Hyperoside alleviates adriamycin-induced podocyte injury via inhibiting mitochondrial fission
por: Chen, Zhuyun, et al.
Publicado: (2017)

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
por: Wang, Qi, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Drp1-dependent mitophagy protects against cisplatin-induced apoptosis of renal tubular epithelial cells by improving mitochondrial function
por: Zhao, Chuanyan, et al.
Publicado: (2017)

The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy
por: Liang, Qian, et al.
Publicado: (2017)

Characteristics of urinary sodium excretion in patients with chronic kidney disease in Jiangsu, China
por: Sun, Lianqin, et al.
Publicado: (2021)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy
por: Lv, Wei, et al.
Publicado: (2021)

Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients
por: Qin, Hua-Zhang, et al.
Publicado: (2017)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2019)

Impact of Overhydration on Left Ventricular Hypertrophy in Patients With Chronic Kidney Disease
por: Sun, Lianqin, et al.
Publicado: (2022)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults
por: Xiang, Xin, et al.
Publicado: (2021)

Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
por: Liang, Shuang, et al.
Publicado: (2023)

Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report
por: Yang, Yan, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018)

TRPC6 Single Nucleotide Polymorphisms and Progression of Idiopathic Membranous Nephropathy
por: Hofstra, Julia M., et al.
Publicado: (2014)

Helper T Cells in Idiopathic Membranous Nephropathy
por: Zhao, Qihan, et al.
Publicado: (2021)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
por: Zhang, Chengning, et al.
Publicado: (2022)

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials
por: Huang, Haiting, et al.
Publicado: (2021)

Association of gut microbiota with idiopathic membranous nephropathy
por: Li, Mengfei, et al.
Publicado: (2022)

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
por: Nikolopoulou, Aikaterini, et al.
Publicado: (2019)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Chapter 7: Idiopathic membranous nephropathy
Publicado: (2012)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy
por: Chen, Xinxin, et al.
Publicado: (2017)

Advances of the experimental models of idiopathic membranous nephropathy
por: Jiang, Han Xue, et al.
Publicado: (2020)

Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
por: An, Xiaofei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7pskbeif91iu8urq4vlh815ilj